Wells Fargo
ELDN icon

Wells Fargo’s Eledon Pharmaceuticals ELDN Stock Holding History

Wells Fargo’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Buy
74,944
+38,375
+105% +$140K ﹤0.01% 4954
2026
Q1 		$113K Sell
36,569
-32,337
-47% -$76.2K ﹤0.01% 5045
2025
Q4 		$104K Buy
68,906
+20,354
+42% +$48.4K ﹤0.01% 5376
2025
Q3 		$126K Buy
48,552
+11,396
+31% +$33.3K ﹤0.01% 5194
2025
Q2 		$101K Buy
+37,156
New +$111K ﹤0.01% 5191
2024
Q2 		– Sell
-189
Closed -$389 – 7050
2024
Q1 		$389 Buy
189
+3
+2% +$5 ﹤0.01% 6336
2023
Q4 		$335 Buy
186
+14
+8% +$19 ﹤0.01% 6474
2023
Q3 		$236 Buy
172
+26
+18% +$35 ﹤0.01% 6544
2023
Q2 		$200 Buy
146
+60
+70% +$125 ﹤0.01% 6704
2023
Q1 		$203 Buy
86
+2
+2% +$5 ﹤0.01% 6771
2022
Q4 		$192 Buy
84
+2
+2% +$5 ﹤0.01% 6630
2022
Q3 		$0 Sell
82
-10
-11% -$32 ﹤0.01% 6809
2022
Q2 		$0 Buy
92
+4
+5% +$12 ﹤0.01% 6957
2022
Q1 		$0 Hold
88
– – ﹤0.01% 7223
2021
Q4 		$0 Hold
88
– – ﹤0.01% 7342
2021
Q3 		$1K Sell
88
-4
-4% -$28 ﹤0.01% 6691
2021
Q2 		$1K Sell
92
-1
-1% -$9 ﹤0.01% 6649
2021
Q1 		$1K Buy
93
+85
+1,063% +$1.28K ﹤0.01% 6709
2020
Q4 		$0 Buy
8
+3
+60% +$57 ﹤0.01% 6588
2020
Q3 		$0 Buy
5
+1
+25% +$10 ﹤0.01% 6438
2020
Q2 		$0 Hold
4
– – ﹤0.01% 6390
2020
Q1 		$0 Buy
+4
New +$38 ﹤0.01% 6325
2016
Q3 		– Hold
0
– – – 6206
2016
Q2 		– Sell
-2
Closed -$2.21K – 6147
2016
Q1 		$1K Buy
+2
New +$1.96K ﹤0.01% 6092
2015
Q4 		– Hold
0
– – – 6263
2015
Q3 		– Sell
-3
Closed -$6.18K – 6055
2015
Q2 		$6K Sell
3
-3
-50% -$5.8K ﹤0.01% 5953
2015
Q1 		$11K Buy
+6
New +$13.2K ﹤0.01% 5591

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Wells Fargo's ELDN Position: Q2 2026 in Review

Wells Fargo increased its Eledon Pharmaceuticals (ELDN) stake by 105% in Q2 2026, buying an estimated $140K and bringing the position to 74,944 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #4954.

Wells Fargo first reported a position in ELDN in Q1 2015 and has held it in 25 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Wells Fargo held 74,944 shares of Eledon Pharmaceuticals worth $295K as of Q2 2026.
  • Wells Fargo bought 38,375 Eledon Pharmaceuticals shares in Q2 2026, an estimated $140K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4954 holding.
  • Wells Fargo first reported a position in Eledon Pharmaceuticals in Q1 2015 and has held it in 25 quarters since.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.